|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Myasthenia Gravis Panel 2
Test Code10104
CPT Codes
83519 (x3)
Includes
Acetylcholine Receptor Binding Antibody
Acetylcholine Receptor Blocking Antibody
Acetylcholine Receptor Modulating Antibody
Acetylcholine Receptor Blocking Antibody
Acetylcholine Receptor Modulating Antibody
Preferred Specimen
2 mL serum
Minimum Volume
0.7 mL
Transport Container
Plastic screw-cap vial
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
See individual tests
Methodology
See individual tests
FDA Status
Acetylcholine Receptor Modulating Antibody: This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Thurs; Report available: 3-6 days
Reference Range
See Laboratory Report
Clinical Significance
Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody.
Performing Laboratory
Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
33608 Ortega Highway |
San Juan Capistrano, CA 92675-2042 |